Sign in
Taking people in BangladeshNo phase

Cabergoline added to letrozole to trigger ovulation in women with polycystic ovary syndrome

Compares cabergoline plus letrozole with letrozole alone in infertile women with PCOS.

Key facts

Who runs it
Mst.Sumyara Khatun
Where
Dhaka, BangladeshSee the site
Trial code
Registry title
Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS
Status
Recruiting
People taking part
72 people, planned
Started
7 Feb 2025
Planned end
30 Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Letrozole 0.5mg
  • Cabergoline 0.5 mg
Record updated
16 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with polycystic ovary syndrome (PCOS) who have trouble getting pregnant and are planned for treatment to help them release an egg (ovulation induction).

Age
18 to 35 years
Sex
Women only
Disease stage
PCOS diagnosed by the Rotterdam criteria, with primary or secondary subfertility (trouble getting pregnant, with or without an earlier pregnancy).
Earlier treatment
People taking metformin cannot join.
Biomarker or test result
Serum prolactin must not be more than 50 ng/ml. Serum TSH must be below 5mIU/L. BMI must be from 18.5 kg/m2 to under 30 kg/m2.

Main reasons for not taking part

  • Other conditions that look like PCOS, such as late onset congenital adrenal hyperplasia or Cushing syndrome
  • Other causes of infertility, such as male factor, endometriosis, pelvic infection (PID), or womb or tube problems
  • Uncontrolled diabetes, high blood pressure, kidney disease or liver disease
  • Allergy to cabergoline or letrozole
  • Taking some medicines, such as domperidone, metoclopramide, haloperidol, risperidone, amitriptyline, clomipramine, verapamil, methyldopa or reserpine

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • PCOS patients diagnosed according to Rotterdam criteria
  • Age: 18-35 years
  • Primary or secondary subfertility
  • Selected for ovulation induction

Who cannot take part

  • Patients on metformin therapy
  • Patient on antiemetic like Domperidone metoclopramide, antipsychotic drug like haloperidol and risperidone, tricyclic antidepressant like amitriptyline, clomipramine, antihypertensive like verapamil, methyldopa, reserpine
  • Women suffered from PCOS like symptom ex. Late onset congenital adrenal hyperplasia, Cushing syndrome
  • Uncontrolled Medical disease (DM, HTN, kidney disease, liver disease)
  • History of hypersensitivity to cabergoline \& letrozole
  • Serum prolactin (more than 50 ng/ml) (Kyritsi et al., 2018)
  • Thyroid dysfunction ( serum TSH ≥5mIU/L)
  • Male factor infertility
  • Women with other infertility factors (endometriosis, PID,uterine \& tubal causes of infertility)
  • BMI:< 18.5 kg/m2 and ≥30 kg/m2

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 35 years old?

Where in Bangladesh

  • Bangladesh Medical UniversityDhaka, BangladeshContact: Mst Sumyara Khatun Medical officer, MSTaking people

About the trial

What the trial wants to find out

Does combined Cabergoline and letrozole increase ovulation rate What medical problems do participants have when taking drug Cabergoline and Letrozole ? Researchers will compare drug combination of Cabergoline and letrozole to letrozole alone to see combined cabergoline and letrozole works better as ovulation induction.

Read full original descriptionShow less

Participants will:

experimental group will receive Cabergoline and Letrozole comparator group will receive letrozole alone TVS Monitoring will be done for 3 cycle for ovarian response

The 2 groups in the trial

  • Experimental arm : Cabergoline and letrozoleTreatment being tested

    participants will receive Tab. cabergoline 0.5 mg 1 tablet at night, two dose at weekly interval (day 2 and day 9 of menstruation/withdrawal bleeding) plus tab. letrozole 5 mg/day at night from day 2 menstruation/withdrawal bleeding for 5 days for consecutive 3 cycles.

    Treatment: Cabergoline 0.5 mg

  • Comparator arm : letrozoleExisting treatment, for comparison

    participants will receive Tab. letrozole 5 mg/day at night from day 2 of menstruation/withdrawal bleeding for 5 days for consecutive 3 cycles.

    Treatment: Letrozole 0.5mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cabergoline and Letrozole Compared to Letrozole Alone for Ovulation Induction in Infertile Women With Polycystic Ovary Syndrome
Plain-language title
Cabergoline added to letrozole to trigger ovulation in women with polycystic ovary syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07255911, who can take part
Record updated
16 December 2025